Halozyme Therapeutics (HALO) Competitors

Halozyme Therapeutics (NASDAQ:HALO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership.

Is HALO or BIIB more profitable?

Halozyme Therapeutics has a net margin of 43.74% compared to Biogen's net margin of 16.87%. Halozyme Therapeutics' return on equity of 157.78% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	43.74%	157.78%	25.34%
Biogen	16.87%	14.98%	8.76%

Does the MarketBeat Community prefer HALO or BIIB?

Biogen received 1295 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. Likewise, 71.28% of users gave Biogen an outperform vote while only 69.06% of users gave Halozyme Therapeutics an outperform vote.

Company	Underperform	Outperform
Halozyme Therapeutics	Outperform Votes 529 69.06%	Underperform Votes 237 30.94%
Biogen	Outperform Votes 1824 71.28%	Underperform Votes 735 28.72%

Do institutionals & insiders have more ownership in HALO or BIIB?

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has more volatility & risk, HALO or BIIB?

Halozyme Therapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500.

Do analysts prefer HALO or BIIB?

Halozyme Therapeutics currently has a consensus target price of $61.90, indicating a potential upside of 15.16%. Biogen has a consensus target price of $191.30, indicating a potential upside of 51.46%. Given Biogen's stronger consensus rating and higher possible upside, analysts clearly believe Biogen is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	2 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.17
Biogen	0 Sell rating(s)	20 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.38

Which has stronger valuation and earnings, HALO or BIIB?

Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.08B	6.11	$281.59M	$3.76	14.30
Biogen	$9.82B	1.89	$1.63B	$10.13	12.47

Does the media favor HALO or BIIB?

In the previous week, Biogen had 17 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 29 mentions for Biogen and 12 mentions for Halozyme Therapeutics. Biogen's average media sentiment score of 1.34 beat Halozyme Therapeutics' score of 0.86 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	23 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biogen beats Halozyme Therapeutics on 10 of the 18 factors compared between the two stocks.